Specific binding agents for KSHV vIL-6 that neutralize a...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S141100, C435S345000, C435S006120

Reexamination Certificate

active

07374756

ABSTRACT:
A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.

REFERENCES:
patent: 5801042 (1998-09-01), Chang et al.
patent: 5849564 (1998-12-01), Chang et al.
patent: 5854398 (1998-12-01), Chang et al.
patent: 5861500 (1999-01-01), Chang et al.
patent: 5948676 (1999-09-01), Chang et al.
patent: WO 98/03657 (1998-01-01), None
patent: WO 98/04576 (1998-02-01), None
Aoki et al., Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6,Blood93(12):4034-4043 (1999).
Aoki et al., Detection of viral interleukin-6 in Karposi's sarcoma-associated herpesvirus-linked diseases.Blood94(10):431a (1999) (Abstract only).
Aoki et al., Indentification of unique binding site for gp130 in viral interleukin-6 encoded by human herpesvirus 8,Blood96(11):572a (2000) (Abstract only).
Aoki et al., Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders,Blood97(7):2173-2176 (2001).
Aoki et al., Serum viral interleukin-6 in AIDS-related multicentric Castleman disease.Blood97(8):2526-2527 (2001).
Asou et al., Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells,Blood91(7):2475-2481 (1998).
Brakenhoff et al., Development of a human interleukin-6 receptor antagonist,Journal of Biological Chemistry369(1):86-93 (1994).
Burger et al., Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells,Blood91(6):1858-1863 (1998).
Chow et al., Structure of an extracellular gp130 cytokine receptor signaling complex,Science291:2150-2155 (2001).
Drexler et al., Constitutive cytokine production by primary effusion (body cavity-based) lymphoma-derived cell lines,Leukemia13(4):634-640 (1999) (Abstract only).
Hideshima et al., Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6,Clinical Cancer Research6:1180-1189 (2000).
Hoischen et al., Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells,Eur. J. Biochem. 267:3604-3612 (2000).
Jones et al., Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells,Blood94(8):2871-2879 (1999).
Molden et al., A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit,Journal of Biological Chemistry272(31) 19625-19631 (1997).
Moore et al., Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV,Science274(5293):1739-1744 (2000).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Specific binding agents for KSHV vIL-6 that neutralize a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Specific binding agents for KSHV vIL-6 that neutralize a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Specific binding agents for KSHV vIL-6 that neutralize a... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3987776

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.